Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05325112
Other study ID # CP- 909-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date July 15, 2022
Est. completion date November 14, 2022

Study information

Verified date January 2023
Source HeartFlow, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective multi-center study. All clinically stable, symptomatic patients who present to the emergency department (ED) or observation unit with suspected coronary artery disease (CAD) and who have at least one ≥40% lesion and no lesion >90% confirmed by CCTA (Coronary Computed Tomography Angiogram) are eligible for enrollment once their CCTA has been completed and their FFR-CT (if applicable) has been ordered. All enrolling sites will have CCTA incorporated into their standard evaluation of chest pain in the ED/observation unit. Non-control sites will have CCTA and FFR-CT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit.


Description:

This is a prospective multi-center study. All clinically stable, symptomatic patients who present to the ED or observation unit with suspected CAD and who have at least one ≥40% lesion and no lesions <90% lesion in a major vessel, confirmed by CCTA, are eligible for enrollment once their CCTA has been completed and FFR-CT (if applicable) has been ordered. All enrolling sites will have CCTA incorporated into their standard evaluation of chest pain in the ED/observation unit. Non-control sites will have CCTA and FFR-CT analysis incorporated into their standard evaluation of chest pain in the ED/observation unit. All participating sites will provide demographics, medical history, CCTA images, FFR-CT (for non-control sites), the decision plan post CCTA and pre FFR-CT (for non-control sites), length of stay for patients in the ED/observation unit/hospital, billing reports (UB-04 preferred), 30-day clinical outcomes, and any other hospital or office visits, imaging, and/or procedural data completed prior to the follow-up 30-day visit. Sites which do not have FFR-CT incorporated into the ED/observation unit will be control sites.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date November 14, 2022
Est. primary completion date November 14, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Clinically stable, symptomatic patients who present to ED/observation unit with suspected CAD 3. CCTA shows at least one =40% lesion and no lesions >90% in at least one major epicardial vessel 4. FFR-CT processed successfully (if applicable) 5. EKG with no acute ischemic changes 6. Willing to comply with all aspects of the protocol, including adherence to follow up visit 7. Agrees to be included in the study 8. Able to provide written informed consent Exclusion Criteria: 1. CCTA showing no =40% lesion in a major epicardial vessel 2. CCTA showing a lesion >90% in a major epicardial vessel 3. CCTA showing other incidental, non-cardiac findings requiring admission, e.g., pneumonia, pulmonary embolism, or aortic dissection 4. Uninterpretable CCTA which is not of diagnostic quality 5. Coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) prior to CCTA acquisition 6. Left main lesion >50% 7. Confirmed acute coronary syndrome (acute myocardial infarction or unstable angina) 8. Known complex congenital heart disease or any history of coronary artery disease 9. Patients with tachycardia or significant arrhythmia which cannot be adequately controlled with medications to allow CTA 10. Any active, serious, life-threatening disease with a life expectancy of less than 2 months 11. Inability to comply with follow-up requirements 12. Currently enrolled in another study utilizing FFR-CT or in an investigational trial that involves a non-approved cardiac drug or device 13. Persons under the protection of justice, guardianship, or curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
FFRCT
FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.

Locations

Country Name City State
United States University Hospital Clevelan Cleveland Ohio
United States UMass Memorial Hospital Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
HeartFlow, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reclassification rate between the coronary management plan based on the review of the CCTA alone compared to the coronary management plan based on the review of the CCTA and the FFR-CT analysis. 30 days
Secondary Cost Utility Analysis Cost measurements to include length of stay in the emergency department and in the hospital overall, secondary coronary artery disease testing, and invasive procedures done. 30 days
Secondary Rate of Major Adverse Coronary Events (MACE) 30 days
Secondary Time to primary diagnosis Time between when the patient first arrives to the emergency department to when the treating physician documents the primary diagnosis. Within 30 days
Secondary Time to discharge Time between when the patient first arrives to the emergency department to the time the patient was discharged from the emergency department or the hospital. Within 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A